Search Results - "Walsh, Meghara K."

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial by Choueiri, Toni K, Halabi, Susan, Sanford, Ben L, Hahn, Olwen, Michaelson, M Dror, Walsh, Meghara K, Feldman, Darren R, Olencki, Thomas, Picus, Joel, Small, Eric J, Dakhil, Shaker, George, Daniel J, Morris, Michael J

“…Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for…”
Get full text

Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study by Flippot, Ronan, McGregor, Bradley Alexander, Flaifel, Abdallah, Gray, Kathryn P., Signoretti, Sabina, Steinharter, John A., Van Allen, Eliezer Mendel, Walsh, Meghara K., Gundy, Katy, Wei, Xiao X., Harshman, Lauren Christine, Vaishampayan, Ulka N., Choueiri, Toni K., McKay, Rana R.

“…Abstract only 4583 Background: NccRCC and ccRCCsd are aggressive tumors associated with poor prognosis and response to therapy. Combination strategies…”
Get full text

Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC) by McKay, Rana R., McGregor, Bradley Alexander, Gray, Kathryn, Steinharter, John A., Walsh, Meghara K., Braun, David A., Flaifel, Abdallah, VanAllen, Eliezer, Wei, Xiao X., Signoretti, Sabina, Harshman, Lauren Christine, Vaishampayan, Ulka N., Choueiri, Toni K.

“…Abstract only 548 Background: NccRCC and sccRCC have historically been underrepresented in clinical trials. Even with targeted therapy, most patients have…”
Get full text

Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC) by McKay, Rana R., Martini, Dylan, Moreira, Raphael Brandao, Hamieh, Lana, Norton, Craig, Mullane, Stephanie Anne, Walsh, Meghara K., Michaelson, Dror, McDermott, David F., VanAllen, Eliezer, Harshman, Lauren Christine, Choueiri, Toni K.

“…Abstract only 467 Background: Nivolumab, a monoclonal antibody against PD-1, has been shown to improve survival for pts with mRCC. The current standard of care…”
Get full text

A video-based, personalized web page (VBPWP) as a complement to clinical trial (CT) patient management by Mills, Hannah, McKay, Rana R., Werner, Lillian, Jacobus, Susanna J., Pace, Amanda Fredericks, Prisby, Judith, Walsh, Meghara K., Choudhury, Atish Dipankar, Choueiri, Toni K., Pomerantz, Mark, Sweeney, Christopher, Polacek, Laura, Taplin, Mary-Ellen

“…Abstract only 266 Background: Most advances in the diagnosis and treatment (T x ) of patients (pts) with genitourinary (GU) cancers are the result of pt…”
Get full text

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial by George, Daniel J., Hessel, Colin, Halabi, Susan, Sanford, Ben L., Michaelson, M. Dror, Hahn, Olwen Mary, Walsh, Meghara K., Olencki, Thomas, Picus, Joel, Small, Eric Jay, Dakhil, Shaker R., Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, Morris, Michael J., Choueiri, Toni K.

“…Abstract only 582 Background: The randomized phase 2 CABOSUN trial (NCT01835158) compared cabozantinib (C) with sunitinib (S) as initial systemic therapy in…”
Get full text

A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies by McKay, Rana R., Werner, Lillian, Harshman, Lauren Christine, Bellmunt, Joaquim, Sweeney, Christopher, Rosenberg, Jonathan E., VanAllen, Eliezer, Walsh, Meghara K., Vaishampayan, Ulka N., McDermott, David F., Choueiri, Toni K.

“…Abstract only…”
Get full text

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma by Choueiri, Toni K., Michaelson, M Dror, Posadas, Edwin M., Sonpavde, Guru, McDermott, David F., Walsh, Meghara K., Wall, Kevin C., Seon, Ben K., Jivani, Manoj A., Adams, Bonne J., Theuer, Charles P.

“…Abstract only 426 Background: Resistance to VEGF-targeted therapy is a major challenge in contemporary treatment of metastatic renal cell carcinoma (mRCC), and…”
Get full text

A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC) by Choueiri, Toni K., Posadas, Edwin M., Sonpavde, Guru, Figlin, Robert A., Walsh, Meghara K., Wall, Kevin C., Seon, Ben K., Jivani, Manoj A., Adams, Bonne J., Theuer, Charles P.

“…Abstract only…”
Get full text

A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates by Choueiri, Toni K., Jacobus, Susanna J., Qu, Angela Q., Sweeney, Christopher, Appleman, Leonard Joseph, Tretter, Christopher P.G., Bubley, Glenn J., Elfiky, Aymen, Park, Rachel, Stack, Edward C., Signoretti, Sabina, Walsh, Meghara K., Steele, Graeme, Hirsch, Michelle S., Krajewski, Katherine Maragaret, Taplin, Mary-Ellen, Rosenberg, Jonathan E., Ross, Robert W.

“…Abstract only 278 Background: ddMVAC is associated with high responses rate (RR) in advanced urothelial cancer (UC). We embarked on a study in MIUC to…”
Get full text